Prson Gautam

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

This study identifies enhanced mitochondrial respiration and glutamine-dependent TCA cycle as vulnerabilities in MYChigh breast cancer cells, showing synthetic lethality with complex I inhibitors.

This paper develops a computational-experimental approach to design patient-specific drug combinations for AML that are synergistic and minimally toxic.

This paper develops a multiobjective optimization method to identify cancer-selective drug combinations, validated in BRAF-V600E melanoma, showing improved selectivity through combinatorial targeting.

comboFM predicts drug combination effects using machine learning, achieving high accuracy in cancer cell line screening and validating novel synergies.

This paper introduces a normalized drug response metric to improve accuracy and consistency in drug sensitivity quantification by accounting for growth rate variations and experimental noise.